インプラント周囲炎における骨破壊と酸化ストレスのマーカー
インプラント周囲炎における唾液およびインプラント周囲溝液中の骨破壊と酸化ストレスマーカーの評価
The aim of this study is to evaluate and compare the levels of bone resorption (RANKL, OPG) and oxidative stress (Nitrotyrosine, NQO1) markers, along with pro-inflammatory cytokines (IL-1β), in the saliva and peri-implant sulcular fluid (PISF) of patients with peri-implantitis, periodontitis, and healthy individuals. The study seeks to determine the diagnostic value of these biomarkers in the early detection and progression of peri-implant diseases.
調査の概要
状態
条件
詳細な説明
Patients applying to the University of Health Sciences, Gulhane Faculty of Dentistry, Department of Periodontology, will be screened according to the inclusion and exclusion criteria. Following clinical and radiographic examinations, participants will be categorized into four groups (n=20 per group): Periodontitis, Peri-implantitis, Periodontal Health, and Peri-implant Health. All clinical parameters, including Plaque Index (PI), Gingival Index (GI), Bleeding on Probing (BOP), Probing Depth (PD), and Clinical Attachment Loss (CAL), will be recorded at six sites per tooth/implant using a Williams periodontal probe.
The biological sample collection protocol will be conducted as follows:
Saliva Collection: To minimize circadian rhythm variations, unstimulated whole saliva samples (3 ml) will be collected between 9:00 AM and 10:00 AM. Patients will be instructed to refrain from eating, drinking, or oral hygiene procedures for at least one hour prior to collection. Samples will be centrifuged at 1,000g for 10 minutes to remove cellular debris, and the supernatant will be stored at -80°C until laboratory analysis.
Peri-implant Sulcular Fluid (PISF) and Gingival Crevicular Fluid (GCF) Collection: Samples will be obtained from the site with the deepest probing depth in each participant. The area will be isolated with cotton rolls and gently dried with an air syringe to prevent salivary contamination. Periopaper strips will be inserted into the sulcus/pocket for 30 seconds. Strips contaminated with blood or visible saliva will be discarded.
Laboratory Analysis: The concentrations of Interleukin-1 beta (IL-1β), Nitrotyrosine, Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL), Osteoprotegerin (OPG), and NAD(P)H: Quinone Oxidoreductase 1 (NQO1) will be quantified in both saliva and PISF/GCF samples using commercially available Enzyme-Linked Immunosorbent Assay (ELISA) kits according to the manufacturer's instructions.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Nurullah Yurdakul, Dr.
- 電話番号:+905340757662
- メール:nurullah.yurdakul@sbu.edu.tr
研究場所
-
-
Ankara
-
Keçiören、Ankara、トルコ(Türkiye)、06010
- 募集
- Gülhane Faculty of Dentistry, University of Health Sciences
-
コンタクト:
- Nurullah Yurdakul
- 電話番号:05340757662
- メール:yurdakul.nurullah@gmail.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Patients who apply to the University of Health Sciences, Gulhane Faculty of Dentistry, Department of Periodontology, and meet the specific clinical and radiographic criteria for peri-implantitis, periodontitis, or health.
説明
Inclusion Criteria:
Systemically healthy volunteers aged 18-65. For Peri-implantitis group: Implants in function for ≥1 year, radiographic bone loss ≥ 2 mm, probing depth (PD) ≥ 5 mm, and presence of bleeding on probing (BOP) or suppuration.
For Periodontitis group: At least one tooth with PD ≥ 4 mm, presence of BOP, and radiographic bone loss.For Healthy groups: PD ≤ 3 mm, no clinical inflammation (BOP-), and no radiographic bone loss.
(According to the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases) -
Exclusion Criteria:Presence of systemic diseases (e.g., diabetes, rheumatoid arthritis, osteoporosis).
Use of antibiotics, anti-inflammatory, or immunosuppressive drugs within the last 3 months.
Pregnancy or breastfeeding.
Smoking (current smokers).
History of periodontal or peri-implant surgical treatment within the last 6 months.
Implant failure (mobility).
Signs of acute infection (fever, systemic symptoms).
-
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:CASE_CONTROL
- 時間の展望:CROSS_SECTIONAL
コホートと介入
グループ/コホート |
|---|
|
Peri-implantitis Group
Patients with at least one dental implant in function for at least 1 year, showing signs of inflammation (BOP/suppuration), probing depth (PD) ≥ 5 mm, and radiographic bone loss ≥ 2 mm. |
|
Periodontitis Group
Patients with at least one tooth having clinical probing depth ≥ 4 mm, presence of bleeding on probing (BOP), and evidence of radiographic alveolar bone loss. |
|
Peri-implant Health Group
Patients with implants in function for at least 1 year, showing no signs of inflammation (no BOP), probing depth ≤ 3 mm, and no radiographic bone loss. |
|
Periodontal Health Group
Systemically healthy individuals with clinical probing depths ≤ 3 mm, minimal plaque and bleeding scores, and no radiographic evidence of bone loss. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Salivary and Peri-implant Sulcular Fluid (PISF) IL-1β Levels.
時間枠:At the baseline clinical examination (Day 0).
|
The concentration of Interleukin-1 beta (IL-1β), a pro-inflammatory cytokine, will be measured in picograms per milliliter (pg/mL) using ELISA kits to evaluate the severity of inflammation and bone destruction. |
At the baseline clinical examination (Day 0).
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Salivary and Peri-implant Sulcular Fluid (PISF) Nitrotyrosine Levels
時間枠:Baseline (at the time of clinical examination)
|
Concentration of Nitrotyrosine will be measured in saliva and PISF samples using ELISA kits. Nitrotyrosine serves as a biochemical marker of nitrosative stress to evaluate oxidative damage. |
Baseline (at the time of clinical examination)
|
|
Salivary and Peri-implant Sulcular Fluid (PISF) NQO1 Levels
時間枠:Baseline (at the time of clinical examination)
|
NAD(P)H: Quinone Oxidoreductase 1 (NQO1) levels will be measured using ELISA kits to assess the local and systemic antioxidant defense response. |
Baseline (at the time of clinical examination)
|
|
Salivary and Peri-implant Sulcular Fluid (PISF) RANKL Levels
時間枠:Baseline (at the time of clinical examination)
|
Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) levels will be measured to evaluate osteoclast activation and bone destruction potential. |
Baseline (at the time of clinical examination)
|
|
Salivary and Peri-implant Sulcular Fluid (PISF) OPG Levels
時間枠:Baseline (at the time of clinical examination)
|
Osteoprotegerin (OPG) levels will be measured. OPG acts as a decoy receptor for RANKL, and its level indicates the body's attempt to inhibit bone resorption. |
Baseline (at the time of clinical examination)
|
|
Clinical Attachment Loss (CAL) and Probing Depth (PD)
時間枠:Baseline (at the time of clinical examination)
|
CAL and PD will be measured in millimeters (mm) at six sites per tooth/implant using a Williams periodontal probe to assess the severity of tissue destruction. |
Baseline (at the time of clinical examination)
|
|
Plaque Index (PI) and Gingival Index (GI)
時間枠:Baseline (at the time of clinical examination)
|
PI and GI will be recorded using Silness-Löe and Löe-Silness indices (scored 0-3) to evaluate oral hygiene status and gingival inflammation. |
Baseline (at the time of clinical examination)
|
協力者と研究者
捜査官
- 主任研究者:Gülbahar Ustaoğlu, Professor、University of Health Sciences, Gulhane Faculty of Dentistry, Department of Periodontology
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- 2025-403
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The individual participant data will not be shared to protect participant privacy.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。